

Anti Diabetic



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Gliclazide 30 mg ER Tablets	Diamicon® Gliclazide MR Tablets 60 mg (Servier, France)	ACTD	N/A	N/A	N	Development Completed as per ROW (CEP Grade)
Gliclazide 60 mg ER Tablets	Diamicon® Gliclazide MR Tablets 60 mg (Servier, France)	ACTD	N/A	N/A	N	Development Completed as per ROW (CEP Grade)
Glimepiride 1 mg Tablets	N/A	ACTD	N/A	N/A	N	Commercialized in ROW markets
Glimepiride 2 mg Tablets	N/A	ACTD	N/A	N/A	N	Commercialized in ROW markets
Glimepiride 3 mg Tablets	N/A	ACTD	N/A	N/A	N	Commercialized in ROW markets
Glimepiride 4 mg Tablets	N/A	ACTD	N/A	N/A	N	Commercialized in ROW markets
Metformin HCl 1000 mg SR + Glimepiride 1 mg Tablets	N/A	ACTD	N/A	Y	Y	Commercialized in India with Abbott, Dr Reddy's Lab, Franco India, Merck, Sanofi
Metformin HCl 1000 mg SR + Glimepiride 2 mg Tablets	N/A	ACTD	N/A	Y	Y	Commercialized in India with Abbott, Dr Reddy's Lab, Franco India, Merck, Sanofi
Metformin HCl 1000 mg SR Tablets	N/A	ACTD	N/A	Y	Y	Commercialized in India with Bayer, Curatus; ROW markets
Metformin HCl 500 mg PR Tablets IP	Glucophage® Metformin HCl XR Tablets 500 mg (BMS, US)	ACTD	N/A	Y	Y	Commercialized in India with Bayer, Curatus; ROW markets
Metformin HCl 500 mg SR + Gliclazide 30 mg SR Tablets	N/A	Non CTD	N/A	N	Y	Commercialized in India with Abbott, Alkem
Metformin HCl 500 mg SR + Gliclazide 60 mg SR Tablets	N/A	Non CTD	N/A	N	Y	Commercialized in India with Abbott, Alkem, Micro Lab
Metformin HCl 500 mg SR + Atorvastatin 10 mg + Glimepiride 2 mg Tablets	Obimet SR® Metformin HCl SR Tablets 500 mg (Abbott India Ltd, India) + Storvas® Atorvastatin 10 mg Tablets (Ranbaxy, India) + Amaryl®2 Glimepiride Tablets 2 mg (Aventis, India)	ACTD	Yes	Y	Y	Development Completed
Metformin HCl 500 mg SR + Atorvastatin 10 mg + Glimepiride 1 mg Tablets	Obimet SR® Metformin HCl SR Tablets 500 mg (Abbott India Ltd, India) + Storvas® Atorvastatin 10 mg Tablets (Ranbaxy, India) + Amaryl®2 Glimepiride Tablets 2 mg (Aventis, India)	ACTD	Yes	Y	Y	Development Completed
Metformin HCl 500 mg SR + Atorvastatin 10 mg Tablets	Obimet® SR Metformin HCl SR Tablets 500 mg (Abbott, India Ltd) + Storvas® Atorvastatin Tablets 10 mg (Ranbaxy, India)	ACTD	Yes	Y	N	Development Completed
Metformin HCl 500 mg SR + Glimepiride 2 mg + Voglibose 0.2 mg Tablets	N/A	Non CTD	N/A	IP	Y	Commercialized in India with Blue cross, Jubilant, Franco, Merck, Curatus, FDC
Metformin HCl 500 mg SR + Glimepiride 2 mg + Voglibose 0.3 mg Tablets	N/A	Non CTD	N/A	IP	N	Development Completed
Metformin HCl 500 mg SR + Pioglitazone 7.5 mg + Gliclazide 30 mg SR Tablets	N/A	Non CTD	N/A	IP	Y	Development Completed

Anti Diabetic continued



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Metformin HCl 500 mg SR + Pioglitazone 7.5 mg + Gliclazide 60 mg SR Tablets	N/A	Non CTD	N/A	IP	Y	Development Completed
Metformin HCl 500 mg SR + Pioglitazone HCl 15 mg Tablets	Glucophage® Metformin HCl XR Tablets 500 mg (BMS, US) + Actos® Pioglitazone HCl Tablets 30 mg (Takeda, US)	ACTD	N/A	Y	Y	Commercialized in India with Abbott, Franco India, Sanofi; ROW markets
Metformin HCl 500 mg SR + Pioglitazone HCl 30 mg Tablets	Glucophage® Metformin HCl XR Tablets 500 mg (BMS, US) + Actos® Pioglitazone HCl Tablets 30 mg (Takeda, US)	ACTD	N/A	Y	Y	Commercialized in ROW markets
Metformin HCl 500 mg SR + Pioglitazone HCl 7.5 mg + Glimepiride 1 mg Tablets	N/A	Non CTD	N/A	IP	Y	Commercialized in India with Alkem, Aristo, Intas
Metformin HCl 500 mg SR + Pioglitazone HCl 7.5 mg + Glimepiride 2 mg Tablets	N/A	Non CTD	N/A	IP	Y	Commercialized in India with Alkem, Aristo, Intas
Metformin HCl 500 mg SR + Voglibose 0.2 mg Tablets	N/A	ACTD	Yes	Y	Y	Commercialized in India with Merck, Sanofi
Metformin HCl 500 mg SR + Voglibose 0.3 mg Tablets	Glucophage® Metformin HCl SR Tablets 500 mg (BMS, US) + Volix® Voglibose Tablets 0.3 mg (Ranbaxy, India)	ACTD	N/A	Y	Y	Commercialized in India with Merck, Sanofi
Metformin HCl 500 mg SR + Fenofibrate 160 mg Tablets	Obimet® Metformin HCl SR Tablets 500 mg (Abbott India Ltd, India) + Stanlip® Fenofibrate Tablets 160 mg (Ranbaxy, India)	ACTD	N/A	Y	N	Development Completed
Metformin HCl 500 mg SR + Glimepiride 1 mg + Voglibose 0.2 mg Tablets	N/A	Non CTD	N/A	IP	Y	Commercialized in India with Blue cross, Jubilant, Franco, Merck, Curatus, FDC
Metformin HCl 500 mg SR + Glimepiride 1 mg + Voglibose 0.3 mg Tablets	N/A	Non CTD	N/A	IP	N	Development Completed
Metformin HCl 500 mg SR + Glimepiride 1 mg Tablets	Glucophage® Metformin HCl XR Tablets 500 mg (BMS,US) + Amaryl®2 Glimepiride Tablets 2 mg (Aventis, India)	ACTD	N/A	Y	Y	Commercialized in India with Curatus, Franco India, Merck; ROW markets
Metformin HCl 500 mg SR + Glimepiride 2 mg Tablets	Glucophage® Metformin HCl XR Tablets 500 mg (BMS,US) +Amaryl®2 Glimepiride Tablets 2 mg (Aventis, India)	ACTD	N/A	Y	Y	Commercialized in with Curatus Franco India, Merck; ROW markets
Metformin HCl 500 mg SR + Methylcobalamin 750 mcg Tablets	N/A	Non CTD	N/A	N	Y	Commercialized in India with Aristo
Metformin HCl 500 mg SR + Pioglitazone 15 mg + Gliclazide 60 mg SR Tablets	Piozone M® Pioglitazone 15 mg + Metformin HCl SR 500 mg Tablets (Abbott Health Care Ltd, India) + Diamicon® Gliclazide XR Tablets 60 mg (Serdia, India)	Non CTD	Yes	Y	Y	Commercialized in India with Micro Lab
Metformin HCl 500 mg SR + Pioglitazone 15 mg+ Gliclazide 30 mg SR Tablets	Piozone M® Pioglitazone 15 mg + Metformin HCl SR 500 mg Tablets (Abbott Health Care Ltd, India) + Diamicon® Gliclazide XR Tablets 60 mg (Serdia, India)	Non CTD	Yes	Y	Y	Commercialized in India with Micro Lab
Metformin HCl SR 750 mg Tablets	Glucophage® Metformin HCl XR Tablets 750 mg (Merck, UK)	ACTD	N/A	IP	N	Commercialized in ROW markets

Anti Diabetic

continued



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Metformin HCl 500 mg SR + Pioglitazone 15 mg+ Glimepiride 1 mg SR Tablets	Obimet SR® Metformin HCl SR Tablets 500 mg (Abbott India Ltd, India) + Pioglar® Pioglitazone 15 mg Tablets (Ranbaxy, India) + Amaryl® Glimepiride Tablets 1 mg (Aventis, India)	ACTD	N/A	Y	Y	Commercialized in India with Dr Reddy's Lab, Franco, Curatus
Metformin HCl 500 mg SR + Pioglitazone 15 mg+ Glimepiride 2 mg SR Tablets	Obimet SR® Metformin HCl SR Tablets 500 mg (Abbott India Ltd, India) + Pioglar® Pioglitazone 15 mg Tablets (Ranbaxy, India) + Amaryl® Glimepiride Tablets 1 mg (Aventis, India)	ACTD	N/A	Y	Y	Commercialized in India with DRL, Franco, Curatus
Pioglitazone 15 mg Tablets	N/A	ACTD	N/A	N/A	N	Commercialized in ROW markets
Pioglitazone 30 mg Tablets	N/A	ACTD	N/A	N/A	N	Commercialized in ROW markets
Voglibose 0.2 mg ODT	N/A	Non CTD	N/A	N/A	Y	Development Completed
Voglibose 0.3 mg ODT	N/A	Non CTD	N/A	N/A	Y	Development Completed

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

Gastrointestinal



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Esomeprazole 20 mg EC + Domperidone 30 mg SR Capsules	N/A	Non CTD	N/A	Y	Y	Commercialized in India with, Glenmark, Unichem
Esomeprazole 40 mg EC + Domperidone 30 mg SR Capsules	N/A	Non CTD	N/A	Y	Y	Commercialized in India with, Glenmark, Unichem
Esomeprazole 40 mg EC + Itopride 150 mg SR Capsules	Ganaton OD® Itopride SR Capsules 150 mg (Abbott India Ltd, India) + Nexpro® Esomeprazole Tablets 40 mg (Torrent, India)	Non CTD	N/A	Y	Y	Development Completed
Itopride HCl 150 mg SR Capsules	Ganaton® Itopride Tablets 50 mg (Abbott India Ltd, India)	Non CTD	Yes	Y	Y	Commercialized in India with Abbott India
Omeprazole 20 mg + Domperidone 30 mg SR Capsules	Omez® Omeprazole Tablets 20 mg (Dr.Reddy's Lab, India) + Domstal OD® Domperidone SR Tablets 30 mg (Torrent, India)	ACTD	N/A	Y	Y	Commercialized in ROW markets
Ondansetron 4 mg ODT	N/A	Non CTD	N/A	N	Y	Commercialized in India with Abbott Healthcare
Ondansetron 8 mg ODT	N/A	Non CTD	N/A	N	Y	Development Completed
Pantoprazole 40 mg + Domperidone 30 mg SR Capsules	Pantocid® Pantoprazole EC Tablets 40 mg (Sun Pharma, India) + Domstal® Domperidone SR Tablets 30 mg (Torrent, India)	ACTD	Yes	Y	Y	Commercialized in India with FDC Ltd, Franco India, Ipca; ROW markets
Pantoprazole 40 mg + Itopride 150 mg SR Capsules	Pantocid® Pantoprazole EC Tablets 40 mg (Sun Pharma, India) + Ganaton® Itopride SR Capsules 150 mg (Abbott, India)	Non CTD	Yes	Y	Y	Commercialized in India with Abbott, Aristo
Pantoprazole 40 mg Buffer Tablets	N/A	ACTD	N/A	Y	Y	Commercialized in ROW markets
Rabeprazole 20 mg EC + Itopride 150 mg SR Capsules	Veloz 20® Rabeprazole Sodium Tablets 20 mg (Torrent, India) + Ganaton® Itopride Tablets 50 mg TID (Abbott India Ltd, India)	Non CTD	N/A	Y	Y	Commercialized in India with Systopic
Rabeprazole Sodim 10 mg EC Capsules	Pariet® Rabeprazole Tablets 20 mg (Eisai, Japan)	ACTD	N/A	Y	N	Commercialized in ROW markets
Rabeprazole Sodium 20 mg Buffer Tablets	Parit® Rabeprazole Tablets 20 mg (Glaxo SmithKline, India)	ACTD	N/A	Y	Y	Commercialized in ROW markets
Rabeprazole Sodium 20 mg EC + Domperidone 30 mg SR Capsules	Domstal OD® Domperidone Tablets 30 mg (Torrent, India) + Pariet® Rabeprazole Tablets 20 mg (Eisai, Japan)	ACTD	N/A	Y	Y	Commercialized in India with, Dr Reddy's Lab, Eisai Pharma, FDC, Jenburkt, ROW markets
Rabeprazole Sodium 20 mg EC Capsules	Pariet® Rabeprazole Tablets 20 mg (Eisai, Japan)	ACTD	N/A	Y	N	Commercialized in ROW markets
Rabeprazole 20 mg Tablets	NA	ACTD	NA	NA	Y	Development Completed

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

Cardiovascular



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Felodipine 2.5 mg ER Tablets	Plendil® Felodipine ER Tablets 10 mg (AstraZeneca LP, US)	ACTD	N/A	N/A	N	Development Completed
Felodipine 5 mg ER Tablets	Plendil® Felodipine ER Tablets 10 mg (AstraZeneca LP, US)	ACTD	N/A	N/A	N	Development Completed
Felodipine 10 mg ER Tablets	Plendil® Felodipine ER Tablets 10 mg (AstraZeneca LP, US)	ACTD	N/A	N/A	N	Development Completed
Fenofibrate 145 mg Tablets	Tricor® Fenofibrate Tablets 145 mg (Abbott, US)	ACTD	N/A	Y	N	Commercialized in ROW markets
Isosorbide Mononitrate 30 mg SR Capsules	N/A	ACTD	N/A	Y	Y	Commercialized in India with Ipca; ROW markets
Isosorbide Mononitrate 60 mg SR Capsules	N/A	ACTD	N/A	Y	Y	Commercialized in ROW markets
Metoprolol 25 mg SR + Isosorbide Mononitrate 30 mg SR Capsules	Imdur® Isosorbide Mononitrate SR Tablets 60 mg (Astrazeneca, India) + Seloken XL® Metoprolol Tartarate Tablets 50 mg (Astrazeneca, India)	ACTD	N/A	Y	Y	Development Completed
Metoprolol 25 mg SR + Isosorbide Mononitrate 60 mg SR Capsules	Imdur® Isosorbide Mononitrate SR Tablets 60 mg (Astrazeneca, India) + Seloken XL® Metoprolol Tartarate Tablets 50 mg (Astrazeneca, India)	ACTD	N/A	Y	Y	Development Completed
Metoprolol 50 mg SR + Amlodipine 5 mg Capsules	Seloken XL® Metoprolol Tartarate Tablets 50 mg (Astrazeneca, India) + Stamlo® Amlodipine Capsules 5 mg (Dr Reddy's Labs, India)	ACTD	N/A	Y	Y	Development Completed
Metoprolol 50 mg SR + Isosorbide Mononitrate 30 mg SR Capsules	Imdur® Isosorbide Mononitrate SR Tablets 60 mg (Astrazeneca, India) + Seloken XL® Metoprolol Tartarate Tablets 50 mg (Astrazeneca, India)	ACTD	N/A	Y	Y	Development Completed
Metoprolol 50 mg SR + Isosorbide Mononitrate 60 mg SR Capsules	Imdur® Isosorbide Mononitrate SR Tablets 60 mg (Astrazeneca, India) + Seloken XL® Metoprolol Tartarate Tablets 50 mg (Astrazeneca, India)	ACTD	N/A	Y	Y	Development Completed
Trimetazidine 60 mg SR Capsules	Flavedon® Trimetazidine Tablets 20 mg (Serdia Pharmaceuticals, India)	ACTD	N/A	Y	Y	Commercialized in India with Abbott, Micro; ROW markets

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

Pain Management



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Aceclofenac 200 mg SR Capsules	N/A	ACTD	N/A	Y	Y	Commercialized in ROW markets
Diclofenac Sodium 100 mg SR + Rabeprazole 20 mg Capsules	Veloz® Rabeprazole Tablets 20 mg (Torrent, India) + Voveran® Diclofenac Sodium SR Tablets 100 mg (Novartis, India)	Non CTD	Yes	Y	Y	Commercialized in India with Abbott
Eperisone 150 mg SR + Diclofenac Sodium 100 mg SR Capsules	Epry® Eperisone Tablets 50 mg (Eisai Co., Japan) + Voveran® Diclofenac Sodium SR Tablets 100 mg (Novartis, India)	ACTD	Yes	Y	Y	Commercialized in India with Abbott, Eisai
Eperisone 150 mg SR Capsules	Epry® Eperisone Tablets 50 mg (Eisai Co., Japan)	ACTD	Yes	Y	Y	Commercialized in India with Abbott, Eisai; ROW markets
Eperisone 75 mg SR + Diclofenac Sodium 100 mg SR Capsules	Epry® Eperisone Tablets 50 mg (Eisai Co., Japan) + Voveran® Diclofenac Sodium SR Tablets 100 mg (Novartis, India)	ACTD	Yes	Y	Y	Development Completed
Eperisone 75 mg SR Capsules	Epry® Eperisone Tablets 50 mg (Eisai Co., Japan)	ACTD	Yes	Y	Y	Development Completed
Pregabalin 75 mg SR + Aceclofenac 200 mg SR tablets	NA	Non CTD	NA	Y	Y	Development completed
Rabeprazole 20 mg EC + Aceclofenac 200 mg SR Capsules	Altraflam® Aceclofenac SR Capsules 200 mg (Ranbaxy, India) + Roles® Rabeprazole EC Tablets 20 mg (Ranbaxy, India)	ACTD	Yes	Y	Y	Commercialized in India with Jenburkt, Sun Pharma ; ROW markets
Tapentadol 100 mg SR Tablets	Tapenta® Tapentadol Tablets 100 mg (Zuventus, India)	Non CTD	N/A	Y	N	Development Completed
Tapentadol 200 mg SR Tablets	Tapenta® Tapentadol Tablets 100 mg (Zuventus, India)	Non CTD	N/A	Y	N	Development Completed
Tapentadol 50 mg SR Tablets	Tapenta® Tapentadol Tablets 100 mg (Zuventus, India)	Non CTD	N/A	Y	N	Development Completed
Thiocolchicoside 16 mg SR + Diclofenac Sodium 100 mg Capsules	Myoril® Thiocolchicoside Capsules 8 mg (Sanofi Aventis, India) + Voveran® Diclofenac Sodium SR Tablets 100 mg (Novartis, India)	Non CTD	Yes	Y	N	Development Completed
Thiocolchicoside 16 mg SR + Aceclofenac 200 mg SR Capsules	Myoril® Thiocolchicoside Capsules 8 mg (Sanofi Aventis, India) + Zerodol® Aceclofenac Tablets 100 mg (Ipca, India)	ACTD	Yes	Y	Y	Commercialized in India with Aristo, Cadila Pharma, Ipca, Wallace
Thiocolchicoside 16 mg SR Capsules	Myoril® Thiocolchicoside Capsules 8 mg (Sanofi Aventis, India)	ACTD	N/A	Y	N	Development Completed
Thiocolchicoside 8 mg SR + Diclofenac Sodium 100 mg SR Capsules	Myoril® Thiocolchicoside Capsules 8 mg (Sanofi Aventis, India) + Voveran® Diclofenac Sodium SR Tablets 100 mg (Novartis, India)	Non CTD	Yes	IP	N	Development Completed
Thiocolchicoside 8 mg SR + Aceclofenac 200 mg SR Capsules	Myoril® Thiocolchicoside Capsules 8 mg (Sanofi Aventis, India) + Zerodol® Aceclofenac Tablets 100 mg (Ipca, India)	ACTD	Yes	Y	Y	Commercialized in India with Aristo, Cadila Pharma, FDC, Innovcare, Ipca, Jenburkt, Wallace
Thiocolchicoside 8 mg SR Capsules	Myoril® Thiocolchicoside Capsules 8 mg (Sanofi Aventis, India)	ACTD	N/A	Y	N	Development Completed
Tolperisone 450 mg SR + Diclofenac Sodium 100 mg SR Tablets	Voveran® Diclofenac Sodium SR Tablets 100 mg (Novartis, India) + Tolfree® Tolperisone HCl Tablets 150 mg (Zydus Cadila, India)	Non CTD	Yes	Y	Y	Commercialized in India with Unichem, Zuventus
Tolperisone 450 mg SR Tablets	Tolfree® Tolperisone HCl Tablets 150 mg (Zydus Cadila, India)	Non CTD	N/A	Y	Y	Development Completed

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

CONFIDENTIAL VERSION 1.5

NOTE: This brochure is NOT AN OFFER FOR SALE by Inventia Healthcare Limited. Products protected by valid patents are not offered for sale in countries where the sale of such products constitute patent infringement. Products protected by patents will not be supplied where the patent is valid. Any reference to "patents" includes Supplementary Protection Certificate (SPC's) for the product protected by those patents.

MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Oxcarbazepine 150 mg SR Tablets	Selzic® Oxcarbazepine Tablets 300 mg BID (Ranbaxy, India)	Non CTD	N/A	Y	Y	Development Completed
Oxcarbazepine 300 mg SR Tablets	Selzic® Oxcarbazepine Tablets 300 mg BID (Ranbaxy, India)	Non CTD	N/A	Y	Y	Commercialized in India with Alkem & Unichem
Oxcarbazepine 600 mg SR Tablets	Selzic® Oxcarbazepine Tablets 300 mg BID (Ranbaxy, India)	Non CTD	N/A	Y	Y	Commercialized in India with Alkem & Unichem
Pregabalin 150 mg SR + Methylcobalamin 1500 mcg Tablets	PEG SR® Pregabalin SR Tablets 300 mg (Ipca, India) + Nuroday® Methylcobalamin Tablets 1500 mcg (Wockhardt, India)	ACTD	N/A	Y	Y	Commercialized in India with Eris, Ipca, ROW markets
Pregabalin 150 mg SR Tablets	Lyrica® Pregabalin Capsules 150 mg (Pfizer, Germany)	ACTD	Yes	Y	Y	Commercialized in India with Eisai, Ipca, ROW markets
Pregabalin 300 mg SR + Methylcobalamin 1500 mcg Tablets	PEG SR® Pregabalin SR Tablets 300 mg (Ipca, India) + Nuroday® Methylcobalamin Tablets 1500 mcg (Wockhardt, India)	ACTD	N/A	Y	Y	Development Completed
Pregabalin 300 mg SR Tablets	Lyrica® Pregabalin Capsules 150 mg (Pfizer, Germany)	ACTD	Yes	Y	Y	Commercialized in ROW markets
Pregabalin 75 mg SR + Methylcobalamin 1500 mcg Tablets	PEG SR® Pregabalin SR Tablets 300 mg (Ipca, India) + Nuroday® Methylcobalamin Tablets 1500 mcg (Wockhardt, India)	ACTD	N/A	Y	Y	Commercialized in India with Aristo, Ipca, Jenburkt, Sanofi, Unichem, Viilbery, Eisai, Zuventus, FDC; ROW markets
Pregabalin 75 mg SR Tablets	Lyrica® Pregabalin Capsules 150 mg (Pfizer, Germany)	ACTD	Yes	Y	Y	Commercialized in India with, Eisai, Ipca, Unichem; ROW markets

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

Urinogenital



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Dapoxetine 30 mg Mouth Dissolving Tablets	Duralast® Dapoxetine Tablets 60 mg (Sun Pharma, India)	ACTD	N/A	IP	N	Commercialized in ROW market
Dapoxetine 60 mg Mouth Dissolving Tablets	Duralast® Dapoxetine Tablets 60 mg (Sun Pharma, India)	ACTD	N/A	IP	N	Commercialized in ROW market
Sildenafil 50 mg Orodispersible Tablets	Viagra® Sildenafil Tablets 50 mg (Pfizer Labs, France)	ACTD	N/A	N/A	N	Commercialized in ROW markets
Tolterodine Tartrate 2 ER Capsules	Detrol LA (Pfizer, USA)	Non CTD	No	Yes	Yes	Commercialized in India with Dr Reddy; ROW markets
Tolterodine Tartrate 4 mg ER Capsules	Detrol LA (Pfizer, USA)	Non CTD	No	Yes	Yes	Commercialized in India with Dr Reddy; ROW markets

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

Anti Infective



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Azithromycin 250 mg Tablets	N/A	Non CTD	N/A	N/A	N	Commercialized in ROW markets
Azithromycin 500 mg Tablets	N/A	Non CTD	N/A	N/A	N	Commercialized in ROW markets
Linezolid 1200 mg SR Tablets	Lizolid® Linezolid Tablets 600 mg (Glenmark, India)	Non CTD	Yes	IP	Y	Commercialized in India with Zuventus

KEY

IP: In Progress N/A: Not Available Y: Yes N: No

Respiratory



MOLECULE	BE REFERENCE PRODUCT	DOSSIER	CT DATA AVAILABILITY	DGCI (Y,N,IP,NA)	LOCAL FDA (Y/N)	COMMERCIALIZATION STATUS
Ambroxol 75 mg SR Capsules	Liquidix® Ambroxol SR Tablets 75 mg (Sandoz-Novartis, India)	Non CTD	N/A	Y	Y	Commercialized in India with Dr Reddy Lab; ROW markets
Levocetirizine Dihydrochloride 5 mg + Ambroxol 75 mg SR Capsules	Teczine® Levocetirizine HCl Tablets 5 mg (Ranbaxy, India Ltd) + Liquidix SR® Ambroxol SR Tablets 75 mg (Sandoz-Novartis, India)	Non CTD	N/A	Y	Y	Commercialized in India with Dr Reddy Lab
Levocetirizine HCl 5 mg Mouth Dissolving Tablets	N/A	ACTD	N/A	Y	Y	Commercialized in India with Bayer; ROW markets

KEY

IP: In Progress N/A: Not Available Y: Yes N: No